Cresilon Closes $25 Million in Series A-4 Financing to Accelerate Global Expansion and Bring Revolutionary Hemostatic Gel to Human Health Market
NEW YORK, Oct. 27, 2022 — Cresilon, Inc., the Brooklyn-based biotechnology company developing and manufacturing innovative hemostatic medical device technologies, today announced the successful completion of a $25 million Series A-4 financing round. The financing will support the company’s efforts to aggressively accelerate its global expansion plan and bring its revolutionary hemostatic gel to the human …